ClinicalTrials.gg
CompletedNCT03333005Updated May 17, 2024

Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia

A Phase 1 interventional study of APX001 with Standard of Care anti-fungal agent in Acute Myeloid Leukemia, sponsored by Basilea Pharmaceutica. Completed at 3 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 282 studies in Leukemia, Myeloid, Acute with a site in Germany — 32 open to participants now, 55 under way, 18 of them phase 3. Leukemia, Myeloid, Acute · Germany.

Enrollment
229th of 262
20 · median 127
Started
2017
with 19 others
Phase 1
46 of 282
3 open now
Registered
191st of 282
by date

Among the 282 studies in Leukemia, Myeloid, Acute with a site in Germany, this one is the 229th largest by enrollment of the 262 interventional ones that give a count, is one of 20 that started in 2017, is one of 46 in phase 1, and was the 191st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

32 of the 282 studies in Leukemia, Myeloid, Acute with a site in Germany are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 282 studies in Leukemia, Myeloid, Acute with a site in Germany, or all of them as a file.
02

Study summary

An open-label, multi-center, Phase Ib study to determine the safety and pharmacokinetics of intravenous and oral APX001 in patients undergoing chemotherapy for Acute Myeloid Leukemia with neutropenia.

A total of 20 patients will be enrolled in this study. 10 patients in Cohort I, intravenous drug dosing and 10 patients will be enrolled in Cohort II, oral drug dosing.

All patients will receive chemotherapy for their AML according to local clinical standard of care as well as antifungal prophylaxis.

APX001 will be administered for 14 consecutive days, beginning on Study Day 3 after onset of chemotherapy

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Provision of written consent
  • Ages 18-75 inclusive, male or female
  • Diagnosis of Acute Myeloid Leukemia
  • Patients entering first induction treatment chemotherapy
  • Expected to be neutropenic (\<500 ANC/ul) for >/= 10 days

Key Exclusion Criteria:

  • Patients who received systemic antifungal therapy for proven or probable fungal infections within the last 12 months
  • Current fever (> 38 degrees Celsius)
  • Concomitant use of rifampin, rifabutin, ergot alkaloids, terfenadine, astemizole, cisapride, pimozide, quinidine, long acting barbiturates, neostigmine and carbamazepine
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    APX001 with Standard of Care Anti-fungal agent

    Drug: APX001 with Standard of Care anti-fungal agent

Interventions

  • DrugAPX001 with Standard of Care anti-fungal agent

    safety assessment

06

What researchers measure

Primary outcomes

  1. Number of patients with treatment-related adverse events as assessed and reported by CTCAE v4.0

    Time frame: One to forty-four days

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    Time frame: One to forty-four days

  2. Peak Plasma Concentration (Cmax)

    Time frame: One to forty-four days

07

Study locations

3 sites
  • University of Cologne, Center for Integrated Oncology (CIO)
    Cologne, 50931, Germany
  • Johannes Gutenberg, University of Mainz
    Mainz, 55131, Germany
  • University of Munich, Grosshadern Campus
    Munich, 81377, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Oct 2018, 10 months.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 10 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2017
First posted
Nov 6, 2017
StartActual
Nov 27, 2017
Primary completionActual
Oct 26, 2018
CompletionActual
Oct 26, 2018
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03333005
Collaborators
The Clinical Trials Centre Cologne
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 27, 2017
Primary completion
Oct 26, 2018
Completion
Oct 26, 2018
Last update
May 17, 2024

Study contacts

Marc Engelhardt
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion